We also found no significant correlation between ELAVL1/CEACAM1 and the recipient/surgical parameters, including age, sex, race, model for end-stage liver disease (MELD) score, pretransplant blood and liver enzyme tests, bilirubin, prothrombin, and cold ischemia time (Supplemental Table 1B). This evidence concerns the gene CEACAM1 and End Stage Liver Disease.